ANDA 212971, held by L. Perrigo. Fexofenadine Hydrochloride.
As of Nov 21, 2026, ANDA 212971 (Fexofenadine Hydrochloride), held by L. Perrigo, was first approved by FDA on Feb 24, 2020, with 3 approved supplements and 0 published complete response letters.
Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 24, 2020 | Original application | Approved | None posted |
| Fexofenadine Hydrochloride60MG · tablet;oral | Fexofenadine Hydrochloride | OTC |
| Fexofenadine Hydrochloride180MG · tablet;oral | Fexofenadine Hydrochloride | OTC |
| Oct 27, 2026 | Supplement 17Labeling · Standard review | Approved | None posted |
| Nov 4, 2022 | Supplement 14Manufacturing | Approved | None posted |
| Jul 8, 2022 | Supplement 9Manufacturing | Approved | None posted |
| Feb 24, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters